N-Methyl-2-(2'-hydroxy-2'-propyl)pyrrolidine | 16226-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-Methyl-2-(2'-hydroxy-2'-propyl)pyrrolidine
• 英文别名: Dimethyl--carbinol；2-(1-methyl-pyrrolidin-2-yl)-propan-2-ol；2-(1-Methylpyrrolidin-2-yl)propan-2-ol
• CAS: 16226-55-4
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: YGJAZXLKYGEPRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  丙酮 、 N-Methyl-2-(tributylstannyl)pyrrolidine 在 正丁基锂 、 四甲基乙二胺 作用下， 生成 N-Methyl-2-(2'-hydroxy-2'-propyl)pyrrolidine
  参考文献：
  名称：

  Alkylation of 2-lithio-N-methylpiperidines and -pyrrolidines: scope, limitations, and stereochemistry

  摘要：

  The scope and limitations of the alkylation of racemic and nonracemic 2-lithiopiperidines and -pyrrolidines, obtained by transmetalation of the corresponding stannanes, is reported. These organolithiums react with a variety of electrophiles to afford 2-substituted pyrrolidines and piperidines in excellent yield. With primary alkyl halides the reaction proceeds with net inversion of configuration at the metal-bearing carbon in the piperidines; in the pyrrolidines there is a mixture of inversion and retention, with the former predominating. With most carbonyl electrophiles (carbon dioxide, dimethyl carbonate, methyl chloroformate, pivaloyl chloride, benzaldehyde, and dialkyl ketones), retention is observed in both cases. Electrophiles such as benzophenone, benzyl bromide, and tert-butyl bromoacetate afford racemic coupling products. A mechanistic interpretation is presented.

  DOI：

  10.1021/jo00123a008

文献信息

• [EN] NAMPT MODULATORS<br/>[FR] MODULATEURS DE NAMPT
  申请人：CYTOKINETICS INC

  公开号：WO2021159015A1

  公开（公告）日：2021-08-12

  Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

  提供了公式（II）的化合物或其药用可接受盐，其中R1、R2、R3、R4、R5、R6和p如本文所定义。还提供了包含公式（II）化合物或其药用可接受盐的药用可接受组合物。还提供了使用公式（II）化合物或其药用可接受盐的方法。
• [EN] NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS D'AMIDE SUBSTITUÉS BÉTULINIQUES UTILISÉS COMME INHIBITEURS DU VIH
  申请人：HETERO RESEARCH FOUNDATION

  公开号：WO2017017630A1

  公开（公告）日：2017-02-02

  The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

  本发明涉及新的取代苦杏仁酸酰胺化合物的化学式(I)；以及其药用盐，其中R1、R2、R3、R4、R5、R6、R7、R8、X、Y、Z1、Z2、Z3和在此定义的化学式(II)。该发明涉及新的取代苦杏仁酸酰胺衍生物、相关化合物和药物组合物，用于治疗病毒性疾病，特别是HIV介导的疾病。
• [EN] SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF<br/>[FR] COMPOSÉ DE PYRAZINE SUBSTITUÉ, COMPOSITION PHARMACEUTIQUE LE COMPRENANT ET UTILISATION ASSOCIÉE<br/>[ZH] 取代吡嗪类化合物，包含其的药物组合物及其用途
  申请人：SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

  公开号：WO2021259077A1

  公开（公告）日：2021-12-30

  本发明属于药物化学领域，涉及取代吡嗪类化合物，包含其的药物组合物及其用途。具体地，本发明涉及一种具有式（I）结构的化合物，其表现出较好的SHP2抑制活性，可以作为高效的SHP2抑制剂，用于预防和/或治疗SHP2相关疾病。
• Fused ring compounds
  申请人：Genentech, Inc.

  公开号：US11236068B2

  公开（公告）日：2022-02-01

  This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.

  本发明涉及式（I）的融合环化合物（如本文进一步详述），该化合物可用于抑制 Ras 蛋白，还涉及包含这些化合物的组合物以及通过施用这些化合物进行治疗的方法。
• NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2069327B1

  公开（公告）日：2013-10-16